IP Library › Granted Patent US 12,465,640
Granted Patent B2
US 12,465,640 · App. 17/310,802 · Granted Nov 11, 2025

Methods and compositions for treating inflammatory and autoimmune conditions with ECM-affinity peptides linked to anti-inflammatory agents

Inventors: Jeffrey A. Hubbell (Chicago, IL); Kiyomitsu Katsumata (Chicago, IL); Ako Ishihara (Chicago, IL); Jun Ishihara (Chicago, IL); Aslan Mansurov (Chicago, IL)
Assignee: The University of Chicago
A61K39/44A61K38/1709A61K38/1774A61K38/1841A61K38/191A61K38/20A61K38/2006A61K38/2026A61K38/2033A61K38/2066A61K38/2073A61K38/215A61K47/643A61P37/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,465,640
App. No.
17/310,802
Granted
Nov 11, 2025
Kind
B2
Abstract

The disclosure relates to the engineering of collagen-binding modification of anti-inflammatory agents using collagen-binding peptide (CBP) and vWF A3 to achieve targeted therapy for inflammatory diseases. Accordingly, embodiments of the disclosure relate to a composition comprising an anti-inflammatory agent operatively linked to an extracellular matrix (ECM)-affinity peptide. Also disclosed are cytokines and anti-inflammatory agents, such as CD200, linked to a serum protein and/or an ECM-affinity peptide. Further aspects of the disclosure relate to a method for treating an autoimmune or inflammatory condition in a subject comprising administering a composition of the disclosure to the subject.

Claims (15)

1 . A method for reducing inflammation in a subject comprising administering to the subject an effective amount of a composition comprising IL-10 linked to a peptide having at least 95% sequence identity to one of SEQ ID NOs: 3, 4, 5, 47, or 52.

2 . The method of claim 1 , wherein the inflammation comprises an inflammatory condition selected from the group consisting of inflammatory bowel disease, idiopathic pulmonary fibrosis, multiple sclerosis, type 1 diabetes, Crohn's disease, psoriasis, acute inflammation, chronic inflammation, neuroinflammation, and rheumatoid arthritis.

3 . The method of claim 1 , wherein the composition is administered systemically.

4 . The method of claim 3 , wherein the composition is administered by intravenous injection.

5 . The method of claim 1 , wherein the composition is administered locally.

6 . The method of claim 5 , wherein the composition is administered to or adjacent to a site of inflammation.

7 . The method of claim 1 , wherein the method further comprises administration of an additional inflammation therapy.

8 . The method of claim 1 , wherein the IL-10 linked to the peptide having 95% sequence identity to one of SEQ ID NOs: 3, 4, 5, 47, or 52 further comprises a serum protein linked to the peptide or IL-10.

9 . The method of claim 8 , wherein the serum protein comprises albumin.

10 . The method of claim 1 , wherein the ratio of peptide having 95% sequence identity to one of SEQ ID NOs: 3, 4, 5, 47, or 52 to the IL-10 is 1:1 to 5:1.

11 . The method of claim 2 , wherein the inflammatory condition comprises inflammatory bowel disease and wherein the inflammatory bowel disease is selected from Crohn's disease, autoimmune-mediated gastrointestinal diseases, colitis, and autoimmune inflammatory bowel disease.

12 . The method of claim 11 , wherein the colitis is selected from ulcerative colitis, colitis ulcerosa, microscopic colitis, collagenous colitis, colitis polyposa, necrotizing enterocolitis, and transmural colitis.

13 . The method of claim 1 , wherein the IL-10 is linked to a peptide having the amino acid sequence of one of SEQ ID NOs: 3, 4, 5, 47, or 52.

14 . The method of claim 1 , wherein the IL-10 is linked to a peptide having the amino acid sequence of SEQ ID NO:47.

15 . The method of claim 1 , wherein the IL-10 is linked to a peptide having the amino acid sequence of SEQ ID NO:52.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 25, 2021
From: HUBBELL, JEFFREY A.; KATSUMATA, KIYOMITSU; ISHIHARA, AKO; ISHIHARA, JUN; MANSUROV, ASLAN
To: THE UNIVERSITY OF CHICAGO
Reel/Frame 057280/0410 →
Continuity (2)
Provisional Application 62809988 · Feb 25, 2019
Related Publication 20220118089A1 · Apr 21, 2022
References Cited (170)
US 6358524B1 · Sedlacek et al. · 2002 [cited by applicant]
US 6617135B1 · Gillies et al. · 2003 [cited by applicant]
US 7018626B2 · Strom et al. · 2006 [cited by applicant]
US 7081354B2 · Fleer et al. · 2006 [cited by applicant]
US 7166577B2 · Otagiri et al. · 2007 [cited by applicant]
US 7253259B2 · Otagiri et al. · 2007 [cited by applicant]
US 7556816B2 · Walker et al. · 2009 [cited by applicant]
US 7867491B2 · Yang et al. · 2011 [cited by applicant]
US 7927596B2 · Grant et al. · 2011 [cited by applicant]
US 7939056B2 · Horwitz et al. · 2011 [cited by applicant]
US 8246960B2 · Chang et al. · 2012 [cited by applicant]
US 8558048B2 · Margolin et al. · 2013 [cited by applicant]
US 8685406B2 · Walker et al. · 2014 [cited by applicant]
US 8734774B2 · Frelinger et al. · 2014 [cited by applicant]
US 8859209B2 · Larsen · 2014 [cited by applicant]
US 8889130B2 · Kamath · 2014 [cited by applicant]
US 8921528B2 · Holt et al. · 2014 [cited by applicant]
US 8927694B2 · McDonagh et al. · 2015 [cited by applicant]
US 9074010B2 · Sheffer et al. · 2015 [cited by applicant]
US 9120875B2 · Gao et al. · 2015 [cited by applicant]
US 9133265B2 · Sleep · 2015 [cited by applicant]
US 9376495B2 · Bonvini et al. · 2016 [cited by applicant]
US 9394374B2 · Hamblin et al. · 2016 [cited by applicant]
US 9493564B2 · Thompson et al. · 2016 [cited by applicant]
US 9675672B2 · Tagaya et al. · 2017 [cited by applicant]
US 9714281B2 · Dasgupta et al. · 2017 [cited by applicant]
US 9775912B2 · Steiner et al. · 2017 [cited by applicant]
US 9879077B2 · Cha · 2018 [cited by applicant]
US 10118949B2 · Abrahmsen et al. · 2018 [cited by applicant]
US 10143726B2 · Oft · 2018 [cited by applicant]
US 10233228B2 · Plumridge et al. · 2019 [cited by applicant]
US 10245298B2 · Murali et al. · 2019 [cited by applicant]
US 10293043B2 · Mumm et al. · 2019 [cited by applicant]
US 10364419B2 · Buller et al. · 2019 [cited by applicant]
US 10457748B2 · Dave et al. · 2019 [cited by applicant]
US 10711050B2 · Schmidt et al. · 2020 [cited by applicant]
US 10934341B2 · Cameron et al. · 2021 [cited by applicant]
US 10934572B2 · Gosselin et al. · 2021 [cited by applicant]
US 11028166B2 · Cini et al. · 2021 [cited by applicant]
US 11046767B2 · Roobrouck et al. · 2021 [cited by applicant]
US 11096997B2 · Mooney et al. · 2021 [cited by applicant]
US 20010056075A1 · Gyuris et al. · 2001 [cited by applicant]
US 20060025573A1 · Gillies et al. · 2006 [cited by applicant]
US 20070041987A1 · Carter · 2007 [cited by applicant]
US 20130123199A1 · Lee · 2013 [cited by applicant]
US 20130288372A1 · Dasgupta et al. · 2013 [cited by applicant]
US 20150038678A1 · Eaton et al. · 2015 [cited by applicant]
US 20150283073A1 · Tang · 2015 [cited by applicant]
US 20160068583A1 · Van Vlasselaer et al. · 2016 [cited by applicant]
US 20160106858A1 · Hall et al. · 2016 [cited by applicant]
US 20170096472A1 · Rosen et al. · 2017 [cited by applicant]
US 20180000962A1 · Eigenbrot, Jr. et al. · 2018 [cited by applicant]
US 20180009869A1 · Lu et al. · 2018 [cited by applicant]
US 20180028679A1 · Kratz et al. · 2018 [cited by applicant]
US 20180280524A1 · Hubbell et al. · 2018 [cited by applicant]
US 20180326080A1 · Deng · 2018 [cited by applicant]
US 20180333464A1 · Mumm et al. · 2018 [cited by applicant]
US 20190070263A1 · Azimi · 2019 [cited by applicant]
US 20190099485A1 · Swartz et al. · 2019 [cited by applicant]
US 20190099487A1 · Mumm et al. · 2019 [cited by applicant]
US 20190127489A1 · Humphreys et al. · 2019 [cited by applicant]
US 20190144529A1 · Adams et al. · 2019 [cited by applicant]
US 20190183992A1 · Sands et al. · 2019 [cited by applicant]
US 20190184012A1 · Qu et al. · 2019 [cited by applicant]
US 20190216898A1 · Wang et al. · 2019 [cited by applicant]
US 20190282692A1 · Bredehorst et al. · 2019 [cited by applicant]
US 20190290688A1 · Bar-Sagi et al. · 2019 [cited by applicant]
US 20190307849A1 · Oft · 2019 [cited by applicant]
US 20190352335A1 · Jeong et al. · 2019 [cited by applicant]
US 20190365819A1 · Jones et al. · 2019 [cited by applicant]
US 20190375799A1 · Ekblad et al. · 2019 [cited by applicant]
US 20190375823A1 · Dixit et al. · 2019 [cited by applicant]
US 20200048325A1 · Zhan et al. · 2020 [cited by applicant]
US 20200055947A1 · Khalil et al. · 2020 [cited by applicant]
US 20200069814A1 · Zhao et al. · 2020 [cited by applicant]
US 20200102368A1 · Andersen et al. · 2020 [cited by applicant]
US 20200102370A1 · Wittrup et al. · 2020 [cited by applicant]
US 20200123228A1 · Hubbell et al. · 2020 [cited by applicant]
US 20200148733A1 · Hinner et al. · 2020 [cited by applicant]
US 20200172480A1 · Zhao et al. · 2020 [cited by applicant]
US 20200179283A1 · Fahmy et al. · 2020 [cited by applicant]
US 20200230250A1 · Park et al. · 2020 [cited by applicant]
US 20200255512A1 · Fuh et al. · 2020 [cited by applicant]
US 20200268884A1 · Markovic et al. · 2020 [cited by applicant]
US 20200276261A1 · Zhao et al. · 2020 [cited by applicant]
US 20200281994A1 · Irvine et al. · 2020 [cited by applicant]
US 20200317749A1 · Dennis et al. · 2020 [cited by applicant]
US 20200339696A1 · Gerstam et al. · 2020 [cited by applicant]
US 20200385442A1 · Sleep et al. · 2020 [cited by applicant]
US 20200390861A1 · Merchant · 2020 [cited by applicant]
US 20200392206A1 · Finnis et al. · 2020 [cited by applicant]
US 20200405850A1 · Irvine et al. · 2020 [cited by applicant]
US 20210009659A1 · Dixit et al. · 2021 [cited by applicant]
US 20210017247A1 · Jones et al. · 2021 [cited by applicant]
US 20210040179A1 · Hubbell et al. · 2021 [cited by applicant]
US 20210046189A1 · Jung et al. · 2021 [cited by applicant]
US 20210070839A1 · Delahay et al. · 2021 [cited by applicant]
US 20210094995A1 · Hubbell et al. · 2021 [cited by applicant]
US 20210115102A1 · Winston et al. · 2021 [cited by applicant]
US 20210121533A1 · Jones et al. · 2021 [cited by applicant]
US 20210139560A1 · Larson et al. · 2021 [cited by applicant]
US 20210163565A1 · Zhong et al. · 2021 [cited by applicant]
US 20210163599A1 · Basran et al. · 2021 [cited by applicant]
US 20210171642A1 · Hubbell et al. · 2021 [cited by applicant]
US 20210188963A1 · Rommelaere et al. · 2021 [cited by applicant]
US 20210188967A1 · Buyse · 2021 [cited by applicant]
US 20210230242A1 · Zhong et al. · 2021 [cited by applicant]
US 20210230285A1 · Cha · 2021 [cited by applicant]
US 20210244812A1 · Hubbell et al. · 2021 [cited by applicant]
CN 109553684 · 2019 [cited by applicant]
JP H11501506 · 1999 [cited by applicant]
JP 2010503396 · 2010 [cited by applicant]
JP 2010534060 · 2010 [cited by applicant]
JP 5178513 · 2013 [cited by applicant]
JP 2017537141 · 2017 [cited by applicant]
JP 2019123719 · 2019 [cited by applicant]
JP 2019523653 · 2019 [cited by applicant]
JP 2020515252 · 2020 [cited by applicant]
JP 2020535264 · 2020 [cited by applicant]
JP 2021006563 · 2021 [cited by applicant]
JP 2021501221 · 2021 [cited by applicant]
JP 6827411 · 2021 [cited by applicant]
JP 2021073291 · 2021 [cited by applicant]
JP 2021515599 · 2021 [cited by applicant]
KR 101286721 · 2013 [cited by applicant]
KR 1010774150 · 2017 [cited by applicant]
WO WO9618412 · 1996 [cited by applicant]
WO WO2009004339 · 2009 [cited by applicant]
WO WO2009013461 · 2009 [cited by applicant]
WO WO2012054929 · 2012 [cited by applicant]
WO WO2012112690 · 2012 [cited by applicant]
WO WO2014139468 · 2014 [cited by applicant]
WO WO2014176284 · 2014 [cited by applicant]
WO WO2016174575 · 2016 [cited by applicant]
WO WO2018069467 · 2018 [cited by applicant]
WO WO2018112394 · 2018 [cited by applicant]
WO WO2018184003 · 2018 [cited by applicant]
WO WO2018195386 · 2018 [cited by applicant]
WO WO2019173289 · 2019 [cited by applicant]
WO WO2019209965 · 2019 [cited by applicant]
WO WO2019222294 · 2019 [cited by applicant]
WO WO2020041758 · 2020 [cited by applicant]
WO WO2020108426 · 2020 [cited by applicant]
WO WO2020176478 · 2020 [cited by applicant]
WO WO2020247973 · 2020 [cited by applicant]
WO WO2021016640 · 2021 [cited by applicant]
WO WO2021091986 · 2021 [cited by applicant]
WO WO2021158938 · 2021 [cited by applicant]
English translation of Office Communication issued in Japanese Patent Application No. 2021-549595, dated Feb. 22, 2024. [cited by applicant]
Extended European Search Report issued in corresponding European Application No. 20762257.2, dated Feb. 6, 2023. [cited by applicant]
Addi et al., “Design and use of chimeric proteins containing a collagen-binding domain for wound healing and bone regeneration” [cited by applicant]
Chaudhury et al., “The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan.” [cited by applicant]
Garamszegi et al. “Extracellular matrix-induced transforming growth factor-β receptor signaling dynamics” [cited by applicant]
Green et al., “Abraxane®, a novel Cremophor®-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer” [cited by applicant]
Hummel et al., “Synthetic Deletion of the Interleukin 23 Receptor (IL-23R) Stalk Region Led to Autonomous IL-23R Homodimerization and Activation” [cited by applicant]
International Search Report and Written Opinion issued in Corresponding PCT Application No. PCT/US2020/070308, dated Nov. 5, 2020. [cited by applicant]
International Search Report and Written Opinion issued in Corresponding PCT Application No. PCT/US2020/019668, dated Jun. 9, 2020. [cited by applicant]
International Search Report and Written Opinion issued in Corresponding PCT Application No. PCT/US2020/70113, dated Sep. 10, 2020. [cited by applicant]
Ishihara et al., “Prolonged residence of an albumin-IL-4 fusion protein in secondary lymphoid organs ameliorates experimental autoimmune encephalomyelitis” [cited by applicant]
Ishihara et al., “Targeted antibody and cytokine cancer immunotherapies through collagen affinity” [cited by applicant]
Katsumata et al., “Targeting inflammatory sites through collagen affinity enhances the therapeutic efficacy of anti-inflammatory antibodies” [cited by applicant]
Kratz et al., “Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding propert… [cited by applicant]
Kratz, F. “Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles.” [cited by applicant]
Puskas et al., “Development of an attenuated interleukin-2 fusion protein that can be activated by tumour-expressed proteases” [cited by applicant]
Sasaki et al., “Engineered collagen-binding serum albumin as a drug conjugate carrier for cancer therapy.” [cited by applicant]
Temming et al., “Evaluation of RGD-targeted albumin carriers for specific delivery of auristatin E to tumor blood vessels” [cited by applicant]
You et al. “The Extracellular Matrix and Remyelination Strategies in Multiple Sclerosis” [cited by applicant]
Yuba et al., “Suppression of Rheumatoid Arthritis by Enhanced Lymph Node Trafficking of Engineered Interleukin-10 in Murine Models” [cited by applicant]
Zhong et al., “710 Development of IL-33 as a novel immunotherapy of cancer” [cited by applicant]
Zorzi et al., “Non-covalent albumin-binding ligands for extending the circulating half-life of small biotherapeutics” [cited by applicant]